Skip to main content

Table 4 Univariable and multivariable Cox proportional hazard analysis of factors associated with overall survival

From: High platelet-to-lymphocyte ratio is associated with poor prognosis in patients with unresectable intrahepatic cholangiocarcinoma receiving gemcitabine plus cisplatin

  Univariable Multivariable
HR P HR P
Age   0.512   
  ≤ 65 1    
  > 65 1.127 (0.788–1.610)    
Sex   0.452   
 Male 0.872 (0.610–1.246)    
 Female 1    
ECOG PS   0.090   0.092
 0 1   1  
  ≥ 1 1.355 (0.953–1.926)   1.372 (0.949–1.984)  
Charlson Commorbidity index   0.730   
 0 1    
  ≥ 1 1.066 (0.742–1.530)    
Chronic hepatitis B   0.246   
 No 1    
 Yes 1.328 (0.822–2.144)    
Chronic hepatitis C   0.736   
 No 1    
 Yes 1.187 (0.437–3.230)    
Liver cirrhosis   0.134   
 No 1    
 Yes 1.531 (0.877–2.673)    
Biliary drainage   0.884   
 No 1    
 Yes 1.043 (0.597–1.821)    
Tumor size   0.207   
  ≤ 7 cm 1    
  > 7 cm 0.799 (0.564, 1.132)    
Vascular invasion   0.346   
 No 1    
 Yes 0.841 (0.587, 1.206)    
Hilar invasion   0.752   
 No 1    
 Yes 0.914 (0.524, 1.596)    
Liver metastasis   0.686   
 No 1    
 Yes 0.930 (0.654–1.322)    
Extrahepatic organ metastasis   0.108   
 No 1    
 Yes 1.332 (0.939–1.889)    
Distant lymph node metastasis   < 0.001   < 0.001
 No 1   1  
 Yes 1.906 (1.309–2.775)   1.929 (1.305–2.851)  
Number of metastatic sites     
 0 1    
 1 2.753 (1.292–5.864) 0.009   
  ≥ 2 2.987 (1.434–6.221) 0.003   
Total bilirubin   0.604   
  ≤ 1.5 x ULN 1    
  > 1.5 x ULN 1.209 (0.590–2.480)    
Alkaline phosphatase   0.008   0.125
  ≤ 1.5 x ULN 1   1  
  > 1.5 x ULN 1.632 (1.138–2.340)   1.337 (0.923–1.939)  
Albumin   0.001   0.043
  < 3.5 g/dL 2.268 (1.424–3.610)   1.632 (1.017–2.618)  
  ≥ 3.5 g/dL 1   1  
CA 19–9   0.530   
  ≤ 37 U/mL 1    
  > 37 U/mL 1.118 (0.790–1.583)    
PLR   < 0.001   0.002
  ≤ 148 1   1  
  > 148 2.332 (1.610–3.378)   1.856 (1.266–2.723)  
NLR   < 0.001   
  ≤ 5 1    
  > 5 2.273 (1.471–3.512)    
LMR   < 0.001   0.041
  < 3.5 2.423 (1.516–3.875)   1.691 (1.023–2.797)  
  ≥ 3.5 1   1  
AGR   0.002   
  < 1.2 1.768 (1.236–2.528)    
  ≥ 1.2 1    
  1. Abbreviations: ECOG Eastern Cooperative Oncology Group; CA 19–9 Carbohydrate antigen 19–9; PLR Platelet-to-lymphocyte ratio; NLR Neutrophil-to-lymphocyte ratio; LMR Lymphocyte-to-monocyte ratio; AGR Albumin-to-globulin ratio